Positive News SentimentPositive NewsNASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis $47.72 +0.23 (+0.48%) Closing price 04:00 PM EasternExtended Trading$47.18 -0.53 (-1.12%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Akero Therapeutics Stock (NASDAQ:AKRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akero Therapeutics alerts:Sign Up Key Stats Today's Range$46.92▼$48.7550-Day Range$45.32▼$56.2852-Week Range$21.34▼$58.40Volume1.16 million shsAverage Volume826,520 shsMarket Capitalization$3.80 billionP/E RatioN/ADividend YieldN/APrice Target$82.50Consensus RatingBuy Company Overview Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Read More Akero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreAKRO MarketRank™: Akero Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 287th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAkero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkero Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Akero Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.99) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -24.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -24.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Akero Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.23% of the float of Akero Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Akero Therapeutics has recently increased by 16.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.75 Percentage of Shares Shorted12.23% of the float of Akero Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Akero Therapeutics has recently increased by 16.90%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment1.58 News SentimentAkero Therapeutics has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Akero Therapeutics this week, compared to 7 articles on an average week.MarketBeat Follows2 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,862,790.00 in company stock.Percentage Held by InsidersOnly 7.07% of the stock of Akero Therapeutics is held by insiders.Read more about Akero Therapeutics' insider trading history. Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Stock News HeadlinesAstraZeneca’s Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in SubgroupJuly 26, 2025 | msn.comAkero Therapeutics shares plunge on liver disease treatment’s mixed ...July 19, 2025 | marketwatch.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 30 at 2:00 AM | Brownstone Research (Ad)Corcept Seeks FDA Approval for Relacorilant in Ovarian CancerJuly 15, 2025 | msn.comAKRO - Akero Therapeutics Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comMJefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t PleasedJune 13, 2025 | msn.comAkero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comAkero Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSee More Headlines AKRO Stock Analysis - Frequently Asked Questions How have AKRO shares performed this year? Akero Therapeutics' stock was trading at $27.82 at the start of the year. Since then, AKRO shares have increased by 71.5% and is now trading at $47.72. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) announced its quarterly earnings results on Monday, May, 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $75 million in an IPO on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' top institutional shareholders include Aberdeen Group plc (0.49%), TD Asset Management Inc (0.24%), Allianz Asset Management GmbH (0.02%) and KLP Kapitalforvaltning AS (0.01%). Insiders that own company stock include Skorpios Trust, G Walmsley Graham, Andrew Cheng, Jonathan Young, Timothy Rolph, Seth Loring Harrison, Catriona Yale, William Richard White, Patrick Lamy, Scott A Gangloff and Tomas J Heyman. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/12/2025Today7/30/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKRO CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Akero Therapeutics$82.50 High Price Target$109.00 Low Price Target$64.00 Potential Upside/Downside+72.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$252.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-15.19% Return on Assets-13.97% Debt Debt-to-Equity Ratio0.03 Current Ratio16.80 Quick Ratio16.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.75 per share Price / Book4.44Miscellaneous Outstanding Shares79,720,000Free Float74,082,000Market Cap$3.80 billion OptionableOptionable Beta-0.15 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AKRO) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.